Neumora Therapeutics (NMRA) awards CFO 175K options

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. (NMRA) reported that its Chief Financial Officer and Principal Accounting Officer, Michael Lee Milligan, received a grant of stock options for 175,000 shares of common stock. The options have an exercise price of $1.52 per share and expire on August 20, 2036.

According to the vesting terms, 25% of the shares vest on the first anniversary of the August 20, 2026 vesting commencement date, and the remaining shares vest in equal monthly installments over the following three years, so that 100% of the option becomes fully vested and exercisable on the fourth anniversary of that date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Milligan Michael Lee

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	175,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 175,000 shares (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Key Figures

Option shares granted: 175,000 shares Exercise price: $1.52 per share Shares underlying option: 175,000 shares +4 more

7 metrics

Option shares granted 175,000 shares Stock option award to CFO on August 20, 2026

Exercise price $1.52 per share Conversion or exercise price for the stock option

Shares underlying option 175,000 shares Common stock underlying the reported stock option

Post-transaction derivative holdings 175,000 options Total stock options held following the reported grant

Initial vesting portion 25% of option shares Vest on first anniversary of August 20, 2026

Monthly vesting fraction 1/48 of total shares Vest monthly after the first anniversary until fully vested

Option term Expires August 20, 2036 Expiration date of the stock option grant

Key Terms

Stock Option, exercise price, Vesting Commencement Date, fully vested and exercisable

4 terms

Stock Option financial

"Stock Option (Right to Buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "1.5200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Vesting Commencement Date financial

"measured from August 20, 2026 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

fully vested and exercisable financial

"100% of the shares subject to the option will be fully vested and exercisable"

FAQ

What equity award did NMRA grant to CFO Michael Lee Milligan?

Neumora Therapeutics (NMRA) granted Michael Lee Milligan stock options for 175,000 shares of common stock with an exercise price of $1.52 per share, expiring on August 20, 2036, as reported in the insider transaction filing.

How do Michael Lee Milligan’s NMRA stock options vest?

For Michael Lee Milligan’s NMRA options, 25% of the 175,000 shares vest on the first anniversary of August 20, 2026, and 1/48 of the total shares vest monthly thereafter so that 100% are vested and exercisable on the fourth anniversary.

What is the exercise price of the NMRA options granted to the CFO?

The stock options granted to the CFO of Neumora Therapeutics (NMRA) have an exercise price of $1.52 per share, giving him the right to buy up to 175,000 shares of NMRA common stock at that price once vested.

When do the NMRA stock options granted to the CFO expire?

The stock options granted to Neumora Therapeutics’ (NMRA) CFO expire on August 20, 2036. Any unexercised portion of the 175,000-share option will no longer be exercisable after this expiration date.

How many NMRA shares will the CFO hold if he exercises the reported option?

If fully exercised, the reported option grant would allow the CFO to acquire 175,000 shares of Neumora Therapeutics (NMRA) common stock at an exercise price of $1.52 per share, subject to the vesting schedule described in the award terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 07:08 PM Accepted by SEC EDGAR 08/21/2026 - 07:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milligan Michael Lee

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL PLACE, SUITE 1

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.52	08/20/2026		A		175,000		(1)	08/20/2036	Common Stock	175,000	$0	175,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Remarks:

Title: Chief Financial Officer & Principal Accounting Officer

	/s/ Michael Milligan	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)